Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RYR2 | Q92736 | 1/20 | 0.42 |
| ▸ | OXTR | P30559 | 1/20 | 0.32 |
| ▸ | PNMT | P11086 | 1/20 | 0.31 |
| ▸ | CD44 | P16070 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL832046 | 0.71 | RYR2 (0.53) | RYR2OXTRPNMTCD44MAOB | |
| SCHEMBL1386398 | 0.67 | RYR2 (0.31) | RYR2 | |
| SCHEMBL2928 | 0.65 | — | — | |
| SCHEMBL29700011 | 0.65 | — | — | |
| SCHEMBL60305 | 0.65 | — | — | |
| SCHEMBL7781679 | 0.64 | RYR2 (0.45) | RYR2OXTRPNMTCD44MAOB | |
| SCHEMBL28993067 | 0.64 | RYR2 (0.45) | RYR2OXTRPNMTCD44MAOB | |
| SCHEMBL4579661 | 0.64 | RYR2 (0.45) | RYR2OXTRPNMTCD44MAOB | |
| SCHEMBL454140 | 0.62 | RYR2 (0.31) | RYR2 | |
| SCHEMBL7164803 | 0.62 | RYR2 (0.44) | RYR2OXTRPNMTCD44MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4764833-B2 | — | — | 2011-09-07 | — | — | JP | claimed |
| EP-1735270-B1 | DIAMINO ALCOHOLS AND THEIR USE AS RENIN INHIBITORS | NOVARTIS AG (CH) | 2010-06-30 | — | — | EP | claimed |
| US-7718675-B2 | Diamino alcohols and their use as renin inhibitor | SPEEDEL EXPERIMENTA AG (CH) | 2010-05-18 | — | — | US | claimed |
| US-20070161622-A1 | 6-Phenyl-2-hydroxy-1,3-hexanediamine derivatives, e.g., 1-{3(S)-Amino-2(S)-hydroxy-5(S)-[4-methoxy-3-(3-methoxypropoxy)benzyl]-methylheptyl}piperidin-2-one hydrochloride; treating hypertension, heart failure, glaucoma, cardiac infarction, kidney failure and restenosis | SPEEDEL EXPERIMENTA AG (CH) | 2007-07-12 | — | — | US | claimed |
| EP-1735270-A1 | DIAMINO ALCOHOLS AND THEIR USE AS RENIN INHIBITORS | Speedel Experimenta AG (CH) | 2006-12-27 | — | — | EP | claimed |
| WO-2005070877-A1 | DIAMINO ALCOHOLS AND THEIR USE AS RENIN INHIBITORS | SPEEDEL EXPERIMENTA AG (CH) | 2005-08-04 | — | — | WO | claimed |
| US-9206173-B2 | Heterocyclic compounds for the treatment of stress-related conditions | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-12-08 | — | — | US | disclosed |
| EP-2435046-B1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF STRESS-RELATED CONDITIONS | OTSUKA PHARMA CO LTD (JP) | 2013-09-04 | — | — | EP | disclosed |
| US-20130005730-A1 | NOVEL 1,3-OXAZOLIDINE COMPOUNDS AND THEIR USE AS RENIN INHIBITORS | MEDIVIR AB (SE) | 2013-01-03 | — | — | US | disclosed |
| EP-2499120-A1 | NOVEL 1,3-OXAZOLIDINE COMPOUNDS AND THEIR USE AS RENIN INHIBITORS | Novadex Pharmaceuticals AB (SE) | 2012-09-19 | — | — | EP | disclosed |
| US-20120065189-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF STRESS-RELATED CONDITIONS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-03-15 | — | — | US | disclosed |
| WO-2011056126-A1 | NOVEL 1,3-OXAZOLIDINE COMPOUNDS AND THEIR USE AS RENIN INHIBITORS | NOVADEX PHARMACEUTICALS AB (SE) | 2011-05-12 | — | — | WO | disclosed |
| WO-2010137738-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF STRESS-RELATED CONDITIONS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-12-02 | — | — | WO | disclosed |
| US-20070021399-A1 | Amido-amino alcohols as therapeutic compounds | SPEEDEL EXPERIMENTA AG (CH) | 2007-01-25 | — | — | US | disclosed |
| EP-1745777-A1 | Amido-aminoalcohols as therapeutic compounds | Speedel Experimenta AG (CH) | 2007-01-24 | — | — | EP | disclosed |
| EP-1745778-A2 | Diaminoalcohols as therapeutic compounds | Speedel Experimenta AG (CH) | 2007-01-24 | — | — | EP | disclosed |
| EP-1735270-A1 | DIAMINO ALCOHOLS AND THEIR USE AS RENIN INHIBITORS | Speedel Experimenta AG (CH) | 2006-12-27 | — | — | EP | disclosed |
| WO-2005070871-A2 | AMINO ALCOHOL DERIVATIVES AND THEIR ACTIVITY AS RENIN INHIBITORS | SPEEDEL EXPERIMENTA AG (CH) | 2005-08-04 | — | — | WO | disclosed |
| WO-2005070877-A1 | DIAMINO ALCOHOLS AND THEIR USE AS RENIN INHIBITORS | SPEEDEL EXPERIMENTA AG (CH) | 2005-08-04 | — | — | WO | disclosed |
| WO-1994029295-A1 | HETEROCYCLIC DERIVATIVES WITH IMMUNOMODULATING ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021399-A1 | Amido-amino alcohols as therapeutic compounds | CTSD, BACE1, CTSL | RYR2 3928/4885OXTR 366/4885PNMT 734/4885 |
| US-20130005730-A1 | NOVEL 1,3-OXAZOLIDINE COMPOUNDS AND THEIR USE AS RENIN INHIBITORS | REN, AGTR1, ACE | RYR2 427/4885OXTR 388/4885PNMT 1853/4885 |
| US-20120065189-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF STRESS-RELATED CONDITIONS | NR3C1, NR3C2, CRH | RYR2 1098/4885OXTR 126/4885PNMT 446/4885 |
| US-20070161622-A1 | 6-Phenyl-2-hydroxy-1,3-hexanediamine derivatives, e.g., 1-{3(S)-Amino-2(S)-hydroxy-5(S)-[4-methoxy-3-(3-methoxypropoxy)benzyl]-methylheptyl}piperidin-2-one hydrochloride; treating hypertension, heart failure, glaucoma, cardiac infarction, kidney failure and restenosis | REN, AGTR1, AGTR2 | RYR2 506/4885OXTR 983/4885PNMT 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.